RNAi trailblazer Alnylam posts promising top-line PhIII snapshot for givosiran, but safety issues drag shares down
Alnylam’s second late-stage RNAi drug just cleared one of the last big hurdles on its way to a possible — maybe even probable — approval at the FDA and EMA for acute hepatic porphyria.
The RNAi trailblazer $ALNY offered up a promising assessment of its Phase III pivotal for givosiran — hitting the primary on reducing the annualized rate of composite porphyria attacks compared to placebo with a p value packed with zeroes: 0.00000001.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 62,300+ biopharma pros reading Endpoints daily — and it's free.